Top
Leber Hereditary Optic Neuropathy (LHON) caused by mutation of the ND4 gene - Healing Genes
576
post-template-default,single,single-post,postid-576,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Leber Hereditary Optic Neuropathy (LHON) caused by mutation of the ND4 gene

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year (REFLECT)

Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year


Phase 3

DESCRIPTION:

Doctors in CA, CO, GA, MA, NY, PA, and TN are recruiting participants with a specific type of Leber’s Hereditary Optic Neuropathy (LHON) to help assess the effectiveness of an investigational gene therapy to improve retina structure and function. The mutation targeted by this treatment is the G11784ND4 mitochondrial mutation, where vision has been lost up to one year.

Participants will be assigned to receive either the investigational drug in both eyes or to receive a placebo injection is one eye and the actual therapy in the second eye. This drug replaces the dysfunctional gene that causes LHON through the mechanism of a harmless virus that inserts the correct gene into the patient’s cells. Patients will be followed up to 2 years post treatment.


PATIENT MUST:

  • Be 15 years of age or older
  • Have vision loss of a certain duration of time due to ND4 LHON, in at least one eye
  • Not have alcoholism, alcohol dependence, or alcohol or drug abuse

THE STUDY INVOLVES:

  1. Prescreening to confirm eligibility of the patient to participate
  2. A single intravitreal injection in each eye
  3. 4 weeks post-treatment, a blood assay will be required
  4. Further follow up will continue to the 2 years post treatment, including lab testing, electrocardiogram, physical evaluation, patient surveys, and particularly vision assessments.

LOCATIONS AND CONTACTS:

Primary contact: Barrett Katz, MD | [email protected] | 646 831 3799


The following locations are participating in the trial:

Doheny Eye Center UCLA Pasadena | Pasadena, CA

University of Colorado Health Eye Center | Aurora, CO

Emory Healthcare – The Emory Clinic | Atlanta, GA

Massachusetts Eye and Ear Infirmary | Boston, MA

Icahn School of Medicine at Mount Sinai | New York, NY

Wills Eye Institute – Ocular Oncology Service | Philadelphia, PA

Vanderbilt Eye Institute | Nashville, TN


SPONSOR INFORMATION:

GenSight Biologics

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03293524

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader